PL3239134T3 - Pirydonoamidy jako modulatory kanałów sodowych - Google Patents

Pirydonoamidy jako modulatory kanałów sodowych

Info

Publication number
PL3239134T3
PL3239134T3 PL17152492T PL17152492T PL3239134T3 PL 3239134 T3 PL3239134 T3 PL 3239134T3 PL 17152492 T PL17152492 T PL 17152492T PL 17152492 T PL17152492 T PL 17152492T PL 3239134 T3 PL3239134 T3 PL 3239134T3
Authority
PL
Poland
Prior art keywords
pyridonamides
sodium channel
channel modulators
modulators
sodium
Prior art date
Application number
PL17152492T
Other languages
English (en)
Inventor
Sara Sabina Hadida Ruah
Corey Anderson
Vijayalaksmi Arumugam
Iuliana Luci Asgian
Brian Richard Bear
Andreas P. Termin
James Philip Johnson
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of PL3239134T3 publication Critical patent/PL3239134T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ink Jet (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL17152492T 2013-01-31 2014-01-29 Pirydonoamidy jako modulatory kanałów sodowych PL3239134T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361759059P 2013-01-31 2013-01-31
EP17152492.9A EP3239134B1 (en) 2013-01-31 2014-01-29 Pyridone amides as modulators of sodium channels
EP14704053.9A EP2953931B1 (en) 2013-01-31 2014-01-29 Pyridone amides as modulators of sodium channels
PCT/US2014/013652 WO2014120808A1 (en) 2013-01-31 2014-01-29 Pyridone amides as modulators of sodium channels

Publications (1)

Publication Number Publication Date
PL3239134T3 true PL3239134T3 (pl) 2021-06-14

Family

ID=50073531

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14704053T PL2953931T3 (pl) 2013-01-31 2014-01-29 Pirydonoamidy jako modulatory kanałów sodowych
PL17152492T PL3239134T3 (pl) 2013-01-31 2014-01-29 Pirydonoamidy jako modulatory kanałów sodowych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14704053T PL2953931T3 (pl) 2013-01-31 2014-01-29 Pirydonoamidy jako modulatory kanałów sodowych

Country Status (34)

Country Link
US (6) US9051270B2 (pl)
EP (3) EP2953931B1 (pl)
JP (4) JP6389194B2 (pl)
KR (2) KR102227592B1 (pl)
CN (2) CN105026373B (pl)
AP (1) AP2015008633A0 (pl)
AR (1) AR094667A1 (pl)
AU (3) AU2014212509B2 (pl)
BR (1) BR112015018289A2 (pl)
CA (1) CA2898866C (pl)
CL (1) CL2015002147A1 (pl)
CY (1) CY1119163T1 (pl)
DK (2) DK3239134T3 (pl)
ES (2) ES2857687T3 (pl)
GE (4) GEAP202113922A (pl)
HR (2) HRP20170787T1 (pl)
HU (2) HUE053448T2 (pl)
IL (2) IL269964B2 (pl)
LT (2) LT2953931T (pl)
MX (2) MX383688B (pl)
NZ (2) NZ710270A (pl)
PE (2) PE20151781A1 (pl)
PH (1) PH12015501661B1 (pl)
PL (2) PL2953931T3 (pl)
PT (2) PT3239134T (pl)
RS (2) RS61503B1 (pl)
RU (1) RU2662223C2 (pl)
SG (2) SG11201505953TA (pl)
SI (2) SI3239134T1 (pl)
SM (2) SMT202100030T1 (pl)
TW (2) TWI655187B (pl)
UA (1) UA120589C2 (pl)
UY (1) UY35288A (pl)
WO (1) WO2014120808A1 (pl)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
BR112014029161A2 (pt) 2012-05-22 2017-06-27 Genentech Inc benzamidas n-substituídas e seu uso no tratamento de dor
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
ES2857687T3 (es) 2013-01-31 2021-09-29 Vertex Pharma Piridona amidas como moduladores de los canales de sodio
CN105073738B (zh) 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
BR112015022488A2 (pt) 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
PE20160548A1 (es) 2013-07-19 2016-05-21 Vertex Pharma Sulfonamidas como moduladores de canales de sodio
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2016191312A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
PE20181003A1 (es) 2015-09-28 2018-06-26 Genentech Inc Compuestos terapeuticos y sus metodos de uso
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
MX2018009870A (es) 2016-02-15 2018-11-29 Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh Inhibidores de taf1 para la terapia del cancer.
WO2017147147A1 (en) * 2016-02-23 2017-08-31 PixarBio Corporation Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
SG11201903348UA (en) 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
WO2018175707A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
EP3625214B1 (en) * 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2019157505A1 (en) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated A method of treating pain
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
KR102860523B1 (ko) 2018-11-02 2025-09-16 머크 샤프 앤드 돔 엘엘씨 Nav1.8 억제제로서의 2-아미노-n-헤테로아릴-니코틴아미드
US12344595B2 (en) 2018-11-02 2025-07-01 Merck Sharp & Dohme Llc 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
BR112021012909A2 (pt) * 2019-01-04 2021-09-14 Jiangsu Hengrui Medicine Co., Ltd. Derivado de 6-oxo-1,6-di-hidropiridazina, método de preparação do mesmo e uso médico do mesmo
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
CN112996774B (zh) * 2019-01-25 2022-11-22 江苏恒瑞医药股份有限公司 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN112996776B (zh) * 2019-02-20 2024-03-15 福建盛迪医药有限公司 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2021018165A1 (zh) * 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用
WO2021032074A1 (zh) * 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) * 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
TWI770607B (zh) * 2019-09-12 2022-07-11 大陸商上海濟煜醫藥科技有限公司 吡啶氮氧化合物及其製備方法和用途
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
CN113045487B (zh) * 2019-12-27 2025-01-17 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN114437062B (zh) * 2020-04-30 2024-05-17 成都海博为药业有限公司 一种可作为钠通道调节剂的化合物及其用途
EP4167994A4 (en) 2020-06-17 2024-07-24 Merck Sharp & Dohme LLC 2-OXO-OXAZOLIDINE-5-CARBOXAMIDE AS NAV1.8 INHIBITORS
JP7323723B2 (ja) 2020-06-17 2023-08-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
CN111808019B (zh) * 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114031518B (zh) 2020-12-08 2023-08-18 成都海博为药业有限公司 一种苄胺或苄醇衍生物及其用途
MX2023013146A (es) 2021-05-07 2023-11-28 Merck Sharp & Dohme Llc Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
AU2022286511A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
KR20240031299A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
JP2024520646A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
UY39882A (es) 2021-08-02 2023-06-15 Eurofarma Laboratorios S A COMPUESTOS NACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
UY39881A (es) 2021-08-02 2023-06-15 Eurofarma Laboratorios S A “COMPUESTOS N-ACILHIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS”
CN116655497B (zh) * 2022-02-25 2025-06-03 中国科学院上海药物研究所 脒类衍生化合物及其制备方法和用途
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
AU2023255771A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN119487003A (zh) 2022-04-22 2025-02-18 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
CN116947713B (zh) * 2022-04-25 2026-03-27 中国科学院上海药物研究所 并环类化合物及其应用
GEAP202516637A (en) 2022-04-25 2025-03-25 Siteone Therapeutics Inc Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
PY2404641A (es) 2023-01-30 2024-10-03 Eurofarma Laboratorios S A COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS
EP4660182A1 (en) 2023-01-30 2025-12-10 Eurofarma Laboratórios S.A. Nav1.7- and/or nav1.8-inhibiting aryl pyridine compounds, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
PY2404093A (es) 2023-01-30 2024-10-03 Eurofarma Laboratorios S A Hidrazidas bloqueadoras de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de los mismos y kits
EP4660184A1 (en) 2023-01-30 2025-12-10 Eurofarma Laboratórios S.A. Nav1.7- and/or nav1.8-inhibiting hydroxamates, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
AR131715A1 (es) 2023-01-30 2025-04-23 Eurofarma Laboratorios S A AMIDAS BLOQUEADORAS DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y KITS
KR20250173577A (ko) 2023-04-19 2025-12-10 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Nav1.8억제제 및 이의 제조 방법 및 용도
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2024367861A1 (en) 2023-10-23 2026-05-07 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2024365648A1 (en) 2023-10-23 2026-04-30 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
TW202606663A (zh) 2024-06-28 2026-02-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH598252A5 (pl) * 1974-01-04 1978-04-28 Hoffmann La Roche
GB1447583A (en) * 1974-02-04 1976-08-25 Ici Ltd Xanthene derivatives
US4086350A (en) * 1974-11-06 1978-04-25 Smithkline Corporation Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
GB1543964A (en) * 1976-04-08 1979-04-11 Ici Ltd Method of antagonising herbicides on soyabean and cotton
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
JP3285391B2 (ja) * 1992-09-01 2002-05-27 日本化学工業株式会社 ２−フェノキシ安息香酸の製造法
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU7712000A (en) 1999-09-24 2001-04-24 Johns Hopkins University School Of Medicine, The Methods for identifying an agent that corrects defective protein folding
JP2003034671A (ja) 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
TW200524888A (en) * 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
RS20060143A (sr) * 2003-09-03 2008-06-05 Pfizer Inc., Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
AP2007003887A0 (en) 2004-07-23 2007-02-28 Pfizer Pyridine derivatives
WO2006133459A1 (en) 2005-06-09 2006-12-14 Vertex Pharmaceuticals Incorporated Indane derivatives as modulators of ion channels
WO2007030618A2 (en) 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of voltage gated ion channels
ES2383090T3 (es) 2005-10-12 2012-06-18 Vertex Pharmaceuticals, Inc. Derivados de bifenilo como moduladores de los canales iónicos dependientes de voltaje
MX2008013194A (es) * 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
KR20100007956A (ko) * 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
NZ581309A (en) 2007-05-25 2012-02-24 Vertex Pharma Ion channel modulators and methods of use
JP5555169B2 (ja) * 2007-10-11 2014-07-23 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
MX2010003864A (es) * 2007-10-11 2010-06-01 Vertex Pharma Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
AU2008310663A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
US8461185B2 (en) * 2007-10-31 2013-06-11 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
CA2745952A1 (en) 2008-12-23 2010-07-01 F.Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
CN105254557A (zh) * 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
WO2011115938A1 (en) * 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
CA2812526A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2012050918A2 (en) * 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
BR112013019211A2 (pt) 2011-02-02 2021-07-06 Vertex Pharma amidas de piperidina espirocíclicas de pirrolopirazina como moduladores de canais de íon
EP2675810A1 (en) * 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
CN103443105A (zh) 2011-02-18 2013-12-11 沃泰克斯药物股份有限公司 作为离子通道调节剂的苯并二氢吡喃-螺环哌啶酰胺
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2012122716A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
BR112013024801A2 (pt) * 2011-03-29 2016-12-20 Sanofi Sa formulações de otamixaban com estabilidade aprimorada
JP5730398B2 (ja) 2011-08-10 2015-06-10 三菱電機株式会社 誘導加熱調理器及びそのプログラム
CN102584774B (zh) * 2011-12-22 2014-08-06 合肥工业大学 一种呫吨酮类衍生物及其用途
WO2013132376A1 (en) 2012-03-06 2013-09-12 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
CN102659628B (zh) * 2012-04-26 2014-07-02 四川大学 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂
CN105073738B (zh) 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
AR094668A1 (es) 2013-01-31 2015-08-19 Vertex Pharma Amidas como moduladores de canales de sodio
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
ES2857687T3 (es) 2013-01-31 2021-09-29 Vertex Pharma Piridona amidas como moduladores de los canales de sodio
PE20160548A1 (es) 2013-07-19 2016-05-21 Vertex Pharma Sulfonamidas como moduladores de canales de sodio
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2019157505A1 (en) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated A method of treating pain

Also Published As

Publication number Publication date
HRP20210349T1 (hr) 2021-04-16
SMT202100030T1 (it) 2021-03-15
MX2021003687A (es) 2023-01-25
JP2019089861A (ja) 2019-06-13
LT3239134T (lt) 2021-02-25
CN108164457A (zh) 2018-06-15
US9393235B2 (en) 2016-07-19
IL240195A0 (en) 2015-09-24
WO2014120808A8 (en) 2015-09-11
UA120589C2 (uk) 2020-01-10
US20140213616A1 (en) 2014-07-31
CN105026373A (zh) 2015-11-04
TWI714967B (zh) 2021-01-01
IL269964B2 (en) 2026-01-01
KR102227592B1 (ko) 2021-03-15
DK3239134T3 (da) 2021-02-22
DK2953931T3 (en) 2017-06-06
MX2015009602A (es) 2015-11-25
UY35288A (es) 2014-08-29
AU2018214105B9 (en) 2020-04-23
TW201443019A (zh) 2014-11-16
EP3239134B1 (en) 2020-12-23
EP3865475A1 (en) 2021-08-18
PL2953931T3 (pl) 2017-09-29
US11673864B2 (en) 2023-06-13
PH12015501661B1 (en) 2020-10-16
US9758483B2 (en) 2017-09-12
PE20151781A1 (es) 2015-12-02
PE20191495A1 (es) 2019-10-21
GEP20217286B (en) 2021-08-25
US10087143B2 (en) 2018-10-02
PT3239134T (pt) 2021-01-28
AU2020204425A1 (en) 2020-07-23
HUE053448T2 (hu) 2021-06-28
KR20210029848A (ko) 2021-03-16
TWI655187B (zh) 2019-04-01
RU2662223C2 (ru) 2018-07-25
CL2015002147A1 (es) 2016-06-03
IL269964A (en) 2019-11-28
AU2014212509B2 (en) 2018-05-10
US20150246028A1 (en) 2015-09-03
KR20150112031A (ko) 2015-10-06
US9051270B2 (en) 2015-06-09
SI2953931T1 (sl) 2017-08-31
GEAP202113922A (en) 2021-02-25
CY1119163T1 (el) 2018-02-14
US20190248745A1 (en) 2019-08-15
JP2016506963A (ja) 2016-03-07
US10738009B2 (en) 2020-08-11
ES2857687T3 (es) 2021-09-29
PT2953931T (pt) 2017-06-14
SMT201700256T1 (it) 2017-09-07
RU2018126184A (ru) 2019-03-12
SG10201706206PA (en) 2017-08-30
CA2898866C (en) 2023-03-07
NZ750187A (en) 2020-09-25
RS61503B1 (sr) 2021-03-31
RU2015136795A (ru) 2017-03-10
GEAP201414909A (pl) 2020-07-10
EP3239134A1 (en) 2017-11-01
WO2014120808A9 (en) 2015-05-14
JP6741704B2 (ja) 2020-08-19
HK1217693A1 (en) 2017-01-20
AP2015008633A0 (en) 2015-07-31
PH12015501661A1 (en) 2015-10-19
HK1244269A1 (en) 2018-08-03
EP2953931B1 (en) 2017-03-01
RU2018126184A3 (pl) 2021-07-26
CN105026373B (zh) 2018-03-30
EP2953931A1 (en) 2015-12-16
JP2021001232A (ja) 2021-01-07
CA2898866A1 (en) 2014-08-07
US20180016235A1 (en) 2018-01-18
AR094667A1 (es) 2015-08-19
US20170037009A1 (en) 2017-02-09
IL269964B1 (en) 2025-09-01
KR102295748B1 (ko) 2021-09-01
SG11201505953TA (en) 2015-08-28
JP2018104453A (ja) 2018-07-05
JP6389194B2 (ja) 2018-09-12
TW201943701A (zh) 2019-11-16
NZ710270A (en) 2020-09-25
GEP20207177B (en) 2020-11-10
RS56015B1 (sr) 2017-09-29
HRP20170787T1 (hr) 2017-08-11
GEAP202014909A (en) 2020-07-10
IL240195B (en) 2019-10-31
MX383688B (es) 2025-03-14
WO2014120808A1 (en) 2014-08-07
AU2014212509A1 (en) 2015-08-06
BR112015018289A2 (pt) 2017-07-18
US20210047271A1 (en) 2021-02-18
AU2018214105A1 (en) 2018-08-30
SI3239134T1 (sl) 2021-03-31
HUE033370T2 (en) 2017-11-28
AU2018214105B2 (en) 2020-04-02
CN108164457B (zh) 2021-07-09
LT2953931T (lt) 2017-07-25
ES2626555T3 (es) 2017-07-25

Similar Documents

Publication Publication Date Title
EP3065716C0 (en) FORMULATIONS
DK3004155T3 (da) Peptidforbindelse
DK3049441T3 (da) Anti-PDL1-antistofformuleringer
PL2970267T6 (pl) Modulatory P2X7
HRP20182159T1 (hr) Poboljšane formulacije adenovirusa
EP2889350A4 (en) ADHESIVE COMPOSITION
DE112014004801A5 (de) Leuchtstoffe
DK2992104T3 (da) Fremgangsmåde til ekspression
FR3009447B1 (fr) Connecteur
EP2975063A4 (en) LOW SUBSTITUTED CELLULOSE ACETATE
DK3027750T3 (da) Biokatalytisk sammensætning
DE102013020972A8 (de) Chirpmodulation
EP3082201A4 (en) INTERCONNECTS
EP2982408A4 (en) INTERCONNECTS
DK3043810T3 (da) Immunsystemsmodulatorer
FR3009137B1 (fr) Connecteur
DK2824505T3 (da) Optisk isolator
EP2999689A4 (en) Cyanoacrylate compositions
EP2983250A4 (en) Connector
FR3009138B1 (fr) Connecteur
EP2979762A4 (en) Isolator system
DK2840222T3 (da) Tætningsliste
DK3007725T3 (da) Beta-glycolipider til anvendelse som adjuvanser
HUE050917T2 (hu) Hidrokortizon-tartalmú készítmény
DK2784331T3 (da) Hydraulisk system